Omega Therapeutics EBIT

The latest EBIT for OMGA is $-74M as of September 2024. That compares with $-120M in the prior-year period — up 37.0% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Omega Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, OMGA's EBIT moved from $-120M to $-74M — a 37.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Omega Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, OMGA currently prints $-74M for EBIT, while the sector average sits near $23B. That is roughly 100.3% below the sector mean. Large gaps often invite a closer look at Omega Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-74M for OMGA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting OMGA's EBIT ($-74M), review year-over-year change from $-120M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.